Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Finished

ClearPlasma An innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding

Coordinator
Plas-Free Ltd, Israel
Runs
1 February 2022 to 31 July 2023
Status
Finished
EU funding
€1.3m
Total cost
€1.8m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190181669

What the project is doing

In the project's own words, from its summary on CORDIS.

Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleeding and death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding.

ClearPlasma™ also allows to reduce up to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.

Who is involved

OrganisationCityCountryRole
Plas-Free LtdNazarethIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI